CN Patent

CN106511357A — 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物

Assigned to Janssen Sciences Ireland ULC · Expires 2017-03-22 · 9y expired

What this patent protects

本发明提供多层片，其包含盐酸利匹韦林、恩曲他滨和富马酸替诺福韦酯。该片剂可用于治疗HIV。

USPTO Abstract

本发明提供多层片，其包含盐酸利匹韦林、恩曲他滨和富马酸替诺福韦酯。该片剂可用于治疗HIV。

Drugs covered by this patent

Patent Metadata

Patent number
CN106511357A
Jurisdiction
CN
Classification
—
Expires
2017-03-22
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.